News

Gocovri Approved by FDA as 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s Patients

The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this common therapy — was approved Thursday, Aug. 24, by the U.S. Food and Drug Administration. The therapy, Gocovri (amantadine) by Adamas Pharmaceuticals, is an long-acting and extended-release capsule, indicated for those…

Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases

The biopharmaceutical company Cavion announced the appointment of a new executive vice president of research and development and chief medical officer to lead efforts advancing therapies based on the company’s T-type calcium channel (Cav3) platform targeting neurological diseases such as Parkinson’s disease (PD). Spyridon “Spyros” Papapetropoulos, MD, PhD, has been named the…

Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show

Singing may help people with Parkinson’s disease — especially in its earlier stages — because it strengthens muscles involved in swallowing and respiratory control, suggests two studies from researchers at Iowa State University. One study, “Therapeutic singing as an early intervention for swallowing in persons with Parkinson’s disease,” was published in…

Klotho Protein Fragment Improves Brain Function, Resilience in Mice; May Eventually Benefit Parkinson’s Patients

The naturally-occurring protein α-klotho improves cognition and brain resilience in mice, and may have potential benefits for Parkinson’s disease (PD) and Alzheimer’s disease (AD), researchers showed. The study, ”Peripheral Elevation of a Klotho Fragment Enhances Brain Function and Resilience in Young, Aging, and α-Synuclein Transgenic Mice,” appeared…